Page last updated: 2024-12-07
leukogen
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 101105 |
| MeSH ID | M0041273 |
Synonyms (26)
| Synonym |
|---|
| AC-15737 |
| STL356027 |
| leucogen |
| nsc400257 |
| 1950-36-3 |
| nsc-400257 |
| 2-(2-ethoxy-2-oxo-1-phenylethyl)-1,3-thiazolidine-4-carboxylic acid |
| leukogen |
| leucoson |
| 2-thiazolidineacetic acid, 4-carboxy-alpha-phenyl-, 2-ethyl ester |
| 2-thiazolidineacetic acid, 4-carboxy-alpha-phenyl-, alpha-ethyl ester |
| ethyl-4-carboxy alpha-phenyl-1,2-thiazolidine acetate |
| 5zb58o726v , |
| unii-5zb58o726v |
| nsc 400257 |
| leyk |
| FT-0603580 |
| AKOS015897259 |
| leucogen [who-dd] |
| BBL023136 |
| 2-(2-ethoxy-2-oxo-1-phenylethyl)thiazolidine-4-carboxylic acid |
| VS-07334 |
| DTXSID20941264 |
| nsc400257; leukogen |
| Q27263098 |
| STARBLD0016636 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| "To investigate whether it is safe to use leucogen tablets 60 mg three times per day (180 mg for a day) and whether this regimen could reduce the incidence of febrile neutropenia caused by chemotherapy." | ( Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia. Cao, J; Huang, XE; Liu, J; Qian, ZY; Shi, L; Wang, L; Wu, XY; Xu, X, 2014) | 0.4 |
| " Treatment-emergent adverse events were attributable to complications of myelosuppressive chemotherapy or the primary disease (i." | ( Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia. Cao, J; Huang, XE; Liu, J; Qian, ZY; Shi, L; Wang, L; Wu, XY; Xu, X, 2014) | 0.4 |
| "This study suggested that leucogen tablets 60mg three times per day (180mg for a day) are safe and could be effective for preventing febrile neutropenia in patients with chemotherapy." | ( Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia. Cao, J; Huang, XE; Liu, J; Qian, ZY; Shi, L; Wang, L; Wu, XY; Xu, X, 2014) | 0.4 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (50.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 88.31
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (88.31) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (7.14%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (92.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||